Nikko Asset Management Americas Inc. Sells 2,664 Shares of Burning Rock Biotech Limited (NASDAQ:BNR)

Nikko Asset Management Americas Inc. decreased its holdings in Burning Rock Biotech Limited (NASDAQ:BNRFree Report) by 4.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,639 shares of the company’s stock after selling 2,664 shares during the quarter. Nikko Asset Management Americas Inc. owned 0.50% of Burning Rock Biotech worth $349,000 at the end of the most recent reporting period.

Separately, Crcm LP acquired a new stake in shares of Burning Rock Biotech during the 4th quarter worth $2,200,000. 30.03% of the stock is owned by institutional investors and hedge funds.

Burning Rock Biotech Stock Performance

Shares of NASDAQ BNR opened at $5.79 on Tuesday. Burning Rock Biotech Limited has a 52 week low of $2.62 and a 52 week high of $8.99. The stock’s fifty day moving average is $6.45 and its 200 day moving average is $5.26. The stock has a market capitalization of $59.32 million, a P/E ratio of -1.93 and a beta of 0.55.

About Burning Rock Biotech

(Free Report)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Read More

Institutional Ownership by Quarter for Burning Rock Biotech (NASDAQ:BNR)

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.